{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:25:53Z","timestamp":1777479953813,"version":"3.51.4"},"reference-count":29,"publisher":"Society of Nuclear Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.2967\/jnumed.121.263611","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T15:21:37Z","timestamp":1653319297000},"page":"1815-1821","source":"Crossref","is-referenced-by-count":20,"title":["Using<sup>68<\/sup>Ga-PSMA-11 PET\/CT for Therapy Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer: Application of EAU\/EANM Recommendations in Clinical Practice"],"prefix":"10.2967","volume":"63","author":[{"given":"Chlo\u00e9 S.","family":"Denis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Cousin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bram De","family":"Laere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Hustinx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brieuc R.","family":"Sautois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Withofs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1602","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"2025012107400780000_63.12.1815.1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000123981.03084.06"},{"key":"2025012107400780000_63.12.1815.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025012107400780000_63.12.1815.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"2025012107400780000_63.12.1815.4","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive 68Ga\u2013prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol."},{"key":"2025012107400780000_63.12.1815.5","unstructured":"Mottet N Cornford P Van den Bergh RCN .EAU-ESTRO-ESUR-SIOG guidelines on prostate cancer. Paper presented at: EAU Annual Congress Amsterdam; July 17\u201326, 2020; Arnhem, The Netherlands."},{"key":"2025012107400780000_63.12.1815.6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025012107400780000_63.12.1815.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.06.030"},{"key":"2025012107400780000_63.12.1815.8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171052"},{"key":"2025012107400780000_63.12.1815.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223099"},{"key":"2025012107400780000_63.12.1815.10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40336-021-00421-4","article-title":"Androgen deprivation therapy and its modulation of PSMA expression in prostate cancer: mini review and case series of patients studied with sequential 68Ga-Ga-PSMA-11 PET\/CT","volume":"9","author":"Mei","year":"2021","journal-title":"Clin Transl Imaging."},{"key":"2025012107400780000_63.12.1815.11","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1200\/JCO.20.00348","article-title":"Exploring spatial-temporal changes in 18F-sodium fluoride PET\/CT and circulating tumor cells in metastatic castration-resistant prostate cancer treated with enzalutamide","volume":"38","author":"Kyriakopoulos","year":"2020","journal-title":"J Clin Oncol."},{"key":"2025012107400780000_63.12.1815.12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.euo.2019.08.012","article-title":"Progression-directed therapy for oligoprogression in castration-refractory prostate cancer","volume":"4","author":"Berghen","year":"2021","journal-title":"Eur Urol Oncol."},{"key":"2025012107400780000_63.12.1815.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02717-7"},{"key":"2025012107400780000_63.12.1815.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2025012107400780000_63.12.1815.15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13550-020-0596-4","article-title":"Interobserver agreement of 68Ga-Ga-PSMA-11 PET\/CT images interpretation in men with newly diagnosed prostate cancer","volume":"10","author":"Derwael","year":"2020","journal-title":"EJNMMI Res."},{"key":"2025012107400780000_63.12.1815.16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s12149-019-01376-3","article-title":"The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival","volume":"33","author":"Acar","year":"2019","journal-title":"Ann Nucl Med."},{"key":"2025012107400780000_63.12.1815.17","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","article-title":"Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617","volume":"47","author":"Ferdinandus","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025012107400780000_63.12.1815.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2025012107400780000_63.12.1815.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3780-7"},{"key":"2025012107400780000_63.12.1815.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.242057"},{"key":"2025012107400780000_63.12.1815.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.224055"},{"key":"2025012107400780000_63.12.1815.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.246603"},{"key":"2025012107400780000_63.12.1815.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.193581"},{"key":"2025012107400780000_63.12.1815.24","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/RLU.0000000000002073","article-title":"Prostate-specific membrane antigen\u2013negative metastases: a potential pitfall in prostate-specific membrane antigen PET","volume":"43","author":"Noto","year":"2018","journal-title":"Clin Nucl Med."},{"key":"2025012107400780000_63.12.1815.25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00259-010-1576-0","article-title":"The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer","volume":"38","author":"Cook","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025012107400780000_63.12.1815.26","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s13139-018-0548-3","article-title":"Evaluation of RECIST, PERCIST, EORTC, and MDA criteria for assessing treatment response with Ga68-PSMA PET-CT in metastatic prostate cancer patient with biochemical progression: a comparative study","volume":"52","author":"Gupta","year":"2018","journal-title":"Nucl Med Mol Imaging."},{"key":"2025012107400780000_63.12.1815.27","first-page":"42","article-title":"Novel framework for treatment response evaluation using PSMA-PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP): an international multicenter study","volume":"40(6 suppl)","author":"Andrei","year":"2022","journal-title":"J Clin Oncol."},{"key":"2025012107400780000_63.12.1815.28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2022.40.6_suppl.010","article-title":"PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)","volume":"40(6 suppl)","author":"Buteau","year":"2022","journal-title":"J Clin Oncol."},{"key":"2025012107400780000_63.12.1815.29","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41416-020-0969-5","article-title":"Plasma tumor DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer","volume":"123","author":"Conteduca","year":"2020","journal-title":"Br J Cancer."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.263611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:12:03Z","timestamp":1737475923000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.263611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,1]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.2967\/jnumed.121.263611"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.263611","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]}}}